Mr. Streeting emphasized the need for careful consideration when dealing with this vulnerable demographic and revealed plans for a clinical trial to gather robust evidence on the efficacy and safety of puberty blockers, set to commence next year. This measure follows prior government actions, including an extensive review led by pediatrician Hilary Cass, which concluded that foundational evidence supporting gender medicine practices, like hormone treatments for delaying puberty, was weak. The review's findings led to broader scrutiny of current healthcare protocols regarding young individuals with gender identity issues.